Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIS/Bev in unresectable or recurrent colorectal cancer
NCT00569790Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Oct 2007
- Primary completion
- Mar 2010
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tegafur, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, bevacizumab in colorectal cancer (CRC), sponsored by Taiho Pharmaceutical Co., Ltd.. Started Oct 2007; status: completed.
02
Drugs
tegafuririnotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00569790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00569790.